GSTP1 and psoriasis: In this work, we presented 8-methoxypsoralen (8-MOP) as a promising GST-π inhibitor; it is a known drug that has been orally and topically used for decades in the treatment of skin disease like psoriasis and eczema (Tzaneva et al., 2009).